Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Actinium Pharmaceuticals (ATNM) Depreciation and Depletion (2021)

Actinium Pharmaceuticals (ATNM) has disclosed Depreciation and Depletion for 2 consecutive years, with $104571.0 as the latest value for Q4 2021.

Quarterly Depreciation and Depletion changed N/A to $104571.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $105000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $173000.0 for FY2025, 12.18% down from the prior year.
Depreciation and Depletion for Q4 2021 was $104571.0 at Actinium Pharmaceuticals, up from $112.0 in the prior quarter.
The five-year high for Depreciation and Depletion was $104571.0 in Q4 2021, with the low at $104571.0 in Q4 2021.